BiotechTube
1Cell.Ai

1Cell.Ai

San Francisco, United States· Est.
1cell.ai
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

1Cell.Ai is a San Francisco-based diagnostics company founded in 2020, focused on revolutionizing precision oncology through an AI-powered single-cell multi-omics platform. The company's technology integrates live CTC and ctDNA analysis, AI-driven digital pathology, and a scalable data ecosystem to deliver actionable insights for therapy decisions, clinical trials, and drug development. Targeting clinicians, pharmaceutical companies, and researchers, 1Cell.Ai positions itself at the intersection of cutting-edge molecular science and machine learning to address tumor heterogeneity and improve cancer patient outcomes.

Oncology

Technology Platform

AI-powered single-cell multi-omic analysis platform integrating live CTC isolation, ctDNA analysis, AI/ML algorithms for data interpretation, and a scalable data ecosystem (1Cell iCore) for precision oncology.

Funding History

2
Total raised:$15M
Series A$12M
Seed$3M

Opportunities

The growing demand for non-invasive, real-time cancer monitoring and personalized treatment strategies presents a large market in precision oncology.
Partnerships with pharmaceutical companies for biomarker discovery and patient stratification in clinical trials offer a significant revenue and validation pathway.
Expansion into new geographic markets, as indicated by the Asia-focused partnership, provides a clear growth vector.

Risk Factors

The company operates in a highly competitive and rapidly evolving landscape with well-capitalized players, risking market saturation.
Demonstrating clinical utility and securing necessary regulatory approvals for its complex AI-driven assays is a costly and uncertain process.
Integrating sophisticated wet-lab and dry-lab technologies into a reliable, scalable, and user-friendly commercial product presents significant execution challenges.

Competitive Landscape

1Cell.Ai competes in the crowded precision oncology diagnostics space. Direct competitors include companies like CellCarta, Mission Bio, and Fluxion Biosciences that offer single-cell analysis platforms, as well as liquid biopsy leaders like Guardant Health and Freenome that leverage AI for blood-based tests. Its differentiation lies in the combined live single-cell (CTC) and ctDNA multi-omic approach, but it must prove this integration provides superior clinical value to gain market share.

More companies in AI / Machine Learning →More companies in United States →